StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) shareholders

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)

Close on Nov 18, 2026Market cap $11.22MP/E –Yield –

Ownership

Who owns Retension Pharmaceuticals's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $369.60K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Pvg Asset Management Corp1,002,0508.30%13G (passive)Oct 9, 2026
The B Group, Inc.
Joint filing with B Group Capital LLC (10.00%), Branden B. Muhl (10.00%)
833,33310.00%13G (passive)Oct 13, 2026
Laurence W. Lytton617,2077.40%13G (passive)Oct 13, 2026
Eric Keller598,5987.07%13D (active)Oct 13, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Eric L. KellerCHIEF EXECUTIVE OFFICER, Director464,407Oct 22, 2026
Robert WongVP, Chief Accounting Officer–Nov 4, 2026
Sabine BissonCHIEF OPERATING OFFICER4,115Oct 13, 2026
Paul SweetnamCHIEF SCIENTIFIC OFFICER409,243Oct 13, 2026
Alison D. SchecterChief Medical Officer–Oct 8, 2026
Alexander Duke SchwartzChief Financial Officer–Oct 8, 2026
Michael J. BerendtDirector6,666Oct 13, 2026
Franklin M. BergerDirector22,517Oct 13, 2026
Donald OldsDirector5,637Oct 13, 2026
Pavan CheruvuDirector–Oct 13, 2026
B Group, Inc.10% owner833,333Oct 16, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Eric L. Keller
CHIEF EXECUTIVE OFFICER, Director
Oct 13, 2026Conversion+31,368––464,407
Eric L. Keller
CHIEF EXECUTIVE OFFICER, Director
Oct 13, 2026Conversion+9,662––433,039
Eric L. Keller
CHIEF EXECUTIVE OFFICER, Director
Oct 13, 2026Buy+20,800$12.00$249.60K423,377
Paul Sweetnam
CHIEF SCIENTIFIC OFFICER
Oct 13, 2026Conversion+2,640––2,640
Paul Sweetnam
CHIEF SCIENTIFIC OFFICER
Oct 13, 2026Conversion+4,026––406,603
Donald Olds
Director
Oct 13, 2026Conversion+5,637––5,637
Sabine Bisson
CHIEF OPERATING OFFICER
Oct 13, 2026Conversion+2,504––4,115
Sabine Bisson
CHIEF OPERATING OFFICER
Oct 13, 2026Conversion+1,611––1,611
Franklin M. Berger
Director
Oct 13, 2026Buy+10,000$12.00$120.00K10,000
Franklin M. Berger
Director
Oct 13, 2026Conversion+12,517––12,517
Michael J. Berendt
Director
Oct 13, 2026Conversion+2,640––6,666
Michael J. Berendt
Director
Oct 13, 2026Conversion+4,026––4,026

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
8.49%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+10.6%
From 0M shares
Short volume, 20 days
44.5%
Of volume reported to FINRA

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Retension Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,377 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?